Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (356)	2/3/1999 7:38:00 PM
From: Robert Dydo	Respond to of 572

The question how successful this agreement can be, will be answered only by the development of this combination of device and the drug. Miravant is in the preclinical trails for oncology treatments, while Xillix technology is basically ready to serve in this area already. I agree that QLT is way ahead compared with Miravant and circumstances of the moment, once again as with Olympus, have taken opportunities away from Xillix for better exposure I suppose, not necessarily QLT was interested. I am hoping since P&U has taken a lead in development of SnET2 from Miravant, they will have a better opportunity to catch up or rather start up in the oncology area with their PhotoPoint. Olympus obviously will play this big brother card in the area of Life-Gi, they may as well pay $30.00 per share and had their way with all the aspects of Xillix work.